PHGDH as a mechanism for resistance in metabolically-driven cancers

Abstract

At the forefront of cancer research is the rapidly evolving understanding of metabolic reprogramming within cancer cells. The expeditious adaptation to metabolic inhibition allows cells to evolve and acquire resistance to targeted treatments, which makes therapeutic exploitation complex but achievable. 3-phosphoglycerate dehydrogenase (PHGDH) is the rate-limiting enzyme of de novo serine biosynthesis and is highly expressed in a variety of cancers, including breast cancer, melanoma, and Ewing’s sarcoma. This review will investigate the role of PHGDH in normal biological processes, leading to the role of PHGDH in the progression of cancer. With an understanding of the molecular mechanisms by which PHGDH expression advances cancer growth, we will highlight the known mechanisms of resistance to cancer therapeutics facilitated by PHGDH biology and identify avenues for combatting PHGDH-driven resistance with inhibitors of PHGDH to allow for the development of effective metabolic therapies.

Keywords

PHGDH / cancer / metabolism / serine / one-carbon metabolism / folate cycle / drug resistance

References

[1] Hanahan D.The hallmarks of cancer..Cell2000;100:57-70

[2] Pavlova NN.The emerging hallmarks of cancer metabolism..Cell Metab2016;23:27-47 PMCID:PMC4715268

[3] Corbin JM.One-carbon metabolism in prostate cancer: the role of androgen signaling..Int J Mol Sci2016;17:1208 PMCID:PMC5000606

[4] Rosenzweig A,Gomes AP.Beyond the warburg effect: how do cancer cells regulate one-carbon metabolism?.Front Cell Dev Biol2018;6:90 PMCID:PMC6103474

[5] Fan J,Liu L,Looper RE.Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate..ACS Chem Biol2015;10:510-6 PMCID:PMC4340346

[6] Yang M.Serine and one-carbon metabolism in cancer..Nat Rev Cancer2016;16:650-62

[7] Gao X,Reid MA,Qiu C.Serine availability influences mitochondrial dynamics and function through lipid metabolism..Cell Rep2018;22:3507-20 PMCID:PMC6054483

[8] Yu L,Ensink E,Yang C.Cysteine catabolism and the serine biosynthesis pathway support pyruvate production during pyruvate kinase knockdown in pancreatic cancer cells..Cancer Metab2019;7:13 PMCID:PMC6937848

[9] Anderson DD.SHMT1 and SHMT2 are functionally redundant in nuclear de novo thymidylate biosynthesis..PLoS One2009;4:e5839 PMCID:PMC2688753

[10] Frezza C.Cancer metabolism: addicted to serine..Nat Chem Biol2016;12:389-90

[11] Newman AC.Serine and functional metabolites in cancer..Trends Cell Biol2017;27:645-57

[12] Mazurek S.Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells..Int J Biochem Cell Biol2011;43:969-80

[13] Chiavarina B,Martinez-Outschoorn UE,Birbe R.Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth..Cancer Biol Ther2011;12:1101-13 PMCID:PMC3335944

[14] Prakasam G,Bamezai RNK.Posttranslational modifications of pyruvate kinase M2: tweaks that benefit cancer..Front Oncol2018;8:22 PMCID:PMC5808394

[15] Iqbal MA,Gopinath P,Bamezai RN.Pyruvate kinase M2 and cancer: an updated assessment..FEBS Lett2014;588:2685-92

[16] Chaneton B,Zheng L,Maddocks ODK.Serine is a natural ligand and allosteric activator of pyruvate kinase M2..Nature2012;491:458-62 PMCID:PMC3894725

[17] Ye J,Tong X,Fan J.Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation..Proc Natl Acad Sci U S A2012;109:6904-9 PMCID:PMC3345000

[18] Sayano T,Kusada W,Esaki K.Adaptive response to l-serine deficiency is mediated by p38 MAPK activation via 1-deoxysphinganine in normal fibroblasts..FEBS Open Bio2016;6:303-16 PMCID:PMC4821351

[19] Jaeken J,Van Maldergem L,Carchon H.3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis..Arch Dis Child1996;74:542-5 PMCID:PMC1511571

[20] Shaheen R,Alhashem A,Zhao Q.Neu-Laxova syndrome, an inborn error of serine metabolism, is caused by mutations in PHGDH..Am J Hum Genet2014;94:898-904 PMCID:PMC4121479

[21] Acuna-Hidalgo R,Kariminejad A,Kariminejad MH.Neu-Laxova syndrome is a heterogeneous metabolic disorder caused by defects in enzymes of the L-serine biosynthesis pathway..Am J Hum Genet2014;95:285-93 PMCID:PMC4157144

[22] Herbig K,Lee LR,Shane B.Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses..J Biol Chem2002;277:38381-9

[23] Sibani S,Pogribny IP,Hiou-Tim F.Studies of methionine cycle intermediates (SAM, SAH), DNA methylation and the impact of folate deficiency on tumor numbers in Min mice..Carcinogenesis2002;23:61-5

[24] Pike MC,Snyderman R.Requirement of S-adenosyl-L-methionine-mediated methylation for human monocyte chemotaxis..Proc Natl Acad Sci U S A1978;75:3928-32 PMCID:PMC392902

[25] Maddocks OD,Adams PD.Serine metabolism supports the methionine cycle and DNA/RNA methylation through de novo ATP synthesis in cancer cells..Mol Cell2016;61:210-21 PMCID:PMC4728077

[26] Maddocks OD,Mason SM,Blyth K.Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells..Nature2013;493:542-6 PMCID:PMC6485472

[27] Lowther J,Dunn TM.Structural, mechanistic and regulatory studies of serine palmitoyltransferase..Biochem Soc Trans2012;40:547-54

[28] Esaki K,Sonoda C,Suzuki T.L-serine deficiency elicits intracellular accumulation of cytotoxic deoxysphingolipids and lipid body formation..J Biol Chem2015;290:14595-609 PMCID:PMC4505526

[29] Lone MA,Alecu I,Hornemann T.1-Deoxysphingolipids..Biochim Biophys Acta Mol Cell Biol Lipids2019;1864:512-21

[30] Alecu I,Behler N,Lamberz C.Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction..J Lipid Res2017;58:42-59 PMCID:PMC5234710

[31] Ou Y,Jiang L,Gu W.p53 Protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation..J Biol Chem2015;290:457-66 PMCID:PMC4281747

[32] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[33] Jia XQ,Zhu HJ,Zhu JH.Increased expression of PHGDH and prognostic significance in colorectal cancer..Transl Oncol2016;9:191-6 PMCID:PMC4907894

[34] Xian Y,Wang X,Wang W.Phosphoglycerate dehydrogenase is a novel predictor for poor prognosis in gastric cancer..Onco Targets Ther2016;9:5553-60 PMCID:PMC5019466

[35] Locasale JW,Melman T,Mattaini KR.Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis..Nat Genet2011;43:869-74 PMCID:PMC3677549

[36] Possemato R,Shaul YD,Kim D.Functional genomics reveal that the serine synthesis pathway is essential in breast cancer..Nature2011;476:346-50 PMCID:PMC3353325

[37] Mullarky E,Vander Heiden MG,Locasale JW.PHGDH amplification and altered glucose metabolism in human melanoma..Pigment Cell Melanoma Res2011;24:1112-5

[38] Issaq SH,Kidner R,Duveau DY.EWS-FLI1-regulated serine synthesis and exogenous serine are necessary for Ewing sarcoma cellular proliferation and tumor growth..Mol Cancer Ther2020;19:1520-9 PMCID:PMC7335326

[39] Jing Z,Aiping D,Shulan Z.Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer..Int J Gynecol Cancer2013;23:1465-9

[40] Song Z,Lu Y,Dong C.PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer..Gene2018;642:43-50

[41] Sun WY,Jung WH.Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype..J Transl Med2016;14:168 PMCID:PMC4898323

[42] Yoon S,Seo AN,Kim HJ.Clinical Implication of Serine Metabolism-Associated Enzymes in Colon Cancer..Oncology2015;89:351-9

[43] Zhang B,Hydbring P,Ouchida AT.PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis..Cell Rep2017;19:2289-303

[44] Zhu J,Wang X,Zhang S.High expression of PHGDH predicts poor prognosis in non-small cell lung cancer..Transl Oncol2016;9:592-9 PMCID:PMC5143353

[45] Ngo B,Osorio-Vasquez V,Bustraan S.Limited environmental serine and glycine confer brain metastasis sensitivity to PHGDH inhibition..Cancer Discov2020;10:1352-73 PMCID:PMC7483776

[46] Nakayama M.Mutant p53 in colon cancer..J Mol Cell Biol2019;11:267-76 PMCID:PMC6487790

[47] Busuttil RA,Haupt S,Wong SQ.Role of p53 in the progression of gastric cancer..Oncotarget2014;5:12016-26 PMCID:PMC4322971

[48] Stretch JR,Ralfkiaer E,Harris AL.Expression of mutant p53 in melanoma..Cancer Res1991;51:5976-9

[49] Bodner SM,Jensen SM,Carbone D.Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation..Oncogene1992;7:743-9

[50] Dando I,Donadelli M.Mutant p53 and mTOR/PKM2 regulation in cancer cells..IUBMB Life2016;68:722-6

[51] Wu S.Dual roles of PKM2 in cancer metabolism..Acta Biochim Biophys Sin2013;45:27-35

[52] Singh M,Warita T,Lee REC.Shift from stochastic to spatially-ordered expression of serine-glycine synthesis enzymes in 3D microtumors..Sci Rep2018;8:9388 PMCID:PMC6010463

[53] Mattaini KR,Vander Heiden MG.The importance of serine metabolism in cancer..J Cell Biol2016;214:249-57 PMCID:PMC4970329

[54] Amelio I,Antonov A,Melino G.Serine and glycine metabolism in cancer..Trends Biochem Sci2014;39:191-8 PMCID:PMC3989988

[55] Estrela JM,Obrador E.Glutathione in cancer biology and therapy..Crit Rev Clin Lab Sci2006;43:143-81

[56] Liu S,Yao K.The antioxidative function of alpha-ketoglutarate and its applications..Biomed Res Int2018;2018:3408467 PMCID:PMC5884300

[57] Badur MG,Parker SJ,McBrayer SK.Oncogenic R132 IDH1 mutations limit NADPH for De Novo Lipogenesis through (D)2-hydroxyglutarate production in fibrosarcoma sells..Cell Rep2018;25:1018-1026.e4 PMCID:PMC6613636

[58] Samanta D.Serine synthesis helps hypoxic cancer stem cells regulate redox..Cancer Res2016;76:6458-62

[59] Murphy JP,Paulo JA,Kennedy BE.The NAD+ salvage pathway supports PHGDH-driven serine biosynthesis..Cell Rep2018;24:2381-91.e5 PMCID:PMC6402325

[60] Yang L,Chen Z,Liang L.Serine catabolism feeds NADH when respiration is impaired..Cell Metab2020;31:809-21.e6 PMCID:PMC7397714

[61] Samanta D,Andrabi SA,Gilkes DM.PHGDH expression is required for mitochondrial redox homeostasis, breast cancer stem cell maintenance, and lung metastasis..Cancer Res2016;76:4430-42

[62] Paul MK.Tyrosine kinase - role and significance in cancer..Int J Med Sci2004;1:101-15 PMCID:PMC1074718

[63] Schöffski P,Clement P,Prenen H.Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review..Ann Oncol2006;17:1185-96

[64] Wei L,Law CT,Shen J.Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC..Nat Commun2019;10:4681 PMCID:PMC6794322

[65] Cesi G,Zimmer A,Haan C.ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells..Mol Cancer2017;16:102 PMCID:PMC5465587

[66] Larkin JMG.Renal cell carcinoma and the use of sorafenib..Ther Clin Risk Manag2006;2:87-98 PMCID:PMC1661649

[67] Desideri E,Baccarini M.Alike but different: RAF paralogs and their signaling outputs..Cell2015;161:967-70

[68] Wieduwilt MJ.The epidermal growth factor receptor family: biology driving targeted therapeutics..Cell Mol Life Sci2008;65:1566-84 PMCID:PMC3060045

[69] Yang W,Cao Y,Bu W.EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis..Mol Cell2012;48:771-84 PMCID:PMC3526114

[70] Yang W,Xia Y,Chen X.ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect..Nat Cell Biol2012;14:1295-304 PMCID:PMC3511602

[71] Normanno N,De Luca A,Salomon DS.Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment..Endocr Relat Cancer2003;10:1-21

[72] Wang Y,Zhou C.Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians..Ther Adv Med Oncol2012;4:19-29 PMCID:PMC3244201

[73] Dong J,Liang Q,Zhou Y.Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase..Theranostics2018;8:1808-23 PMCID:PMC5858502

[74] Lee JW,Ju C.Hypoxia signaling in human diseases and therapeutic targets..Exp Mol Med2019;51:1-13 PMCID:PMC6586801

[75] Gordan JD,Hu CJ,Simon MC.HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity..Cancer Cell2007;11:335-47 PMCID:PMC3145406

[76] Yoshino H,Miyamoto K,Sakaguchi T.PHGDH as a key enzyme for serine biosynthesis in HIF2α-targeting therapy for renal cell carcinoma..Cancer Res2017;77:6321-9 PMCID:PMC5893502

[77] Ye J,Venneti S,Pawel BR.Serine catabolism regulates mitochondrial redox control during hypoxia..Cancer Discov2014;4:1406-17 PMCID:PMC4258153

[78] Zhao E,Xia Y,Ye B.KDM4C and ATF4 Cooperate in transcriptional control of amino acid metabolism..Cell Rep2016;14:506-19 PMCID:PMC4731315

[79] Selvarajah B,Platé M,Forty EJ.mTORC1 amplifies the ATF4-dependent de novo serine-glycine pathway to supply glycine during TGF-β1-induced collagen biosynthesis..Sci Signal2019;12:eaav3048 PMCID:PMC6584619

[80] Xia Y,Ding J,Alptekin A.Metabolic reprogramming by MYCN confers dependence on the serine-glycine-one-carbon biosynthetic pathway..Cancer Res2019;79:3837-50 PMCID:PMC6679782

[81] Wang J,Chen H,Guo H.FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma..Oncogene2019;38:6737-51

[82] Chng WJ,Chung TH,Gonzalez-Paz N.Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma..Leukemia2011;25:1026-35 PMCID:PMC3432644

[83] Masaki R.Mechanism of action of bortezomib in multiple myeloma therapy..Int J Myeloma2016;6:1-6

[84] Rizzieri D,Kang Y.Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma..J Cancer Metastasis Treat2019;5:26 PMCID:PMC6476731

[85] Wu X,Zhang J,Wu Y.Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma..Br J Haematol2020;190:52-66

[86] Zaal EA,Jansen G,Cloos J.Bortezomib resistance in multiple myeloma is associated with increased serine synthesis..Cancer Metab2017;5:7 PMCID:PMC5575874

[87] Dahlman KB,Hutchinson K,Hucks D.BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors..Cancer Discov2012;2:791-7 PMCID:PMC3449158

[88] McCain J.The MAPK (ERK) pathway: investigational combinations for the treatment of BRAF-mutated metastatic melanoma..P T2013;38: PMCID:PMC3628180

[89] Heppt MV,Engel J,Eckel R.Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care..BMC Cancer2017;17:536 PMCID:PMC5553744

[90] Cheng Y.Current Development Status of MEK Inhibitors..Molecules2017;22:1551 PMCID:PMC6151813

[91] Nguyen MQ,Purwin TJ,Davies MA.Targeting PHGDH upregulation reduces glutathione levels and resensitizes resistant NRAS-mutant melanoma to MAPK kinase inhibition..J Invest Dermatol2020;S0022-202X(20)31406-8:

[92] Ross KC,Marion CD,Bhattacharjee V.Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells..Mol Cancer Ther2017;16:1596-609 PMCID:PMC5544579

[93] Jing Z,Xia L,Yafei Q.Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3..Cancer Biol Ther2015;16:541-8 PMCID:PMC4622468

[94] Teng PN,Hood BL,Hamilton CA.Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes..Br J Cancer2014;110:123-32 PMCID:PMC3887292

[95] Lee D.The folate cycle is a new metabolic weakness of cancer..Mol Cell Oncol2017;4:e1327004 PMCID:PMC5706950

[96] Hagner N.Cancer chemotherapy: targeting folic acid synthesis..Cancer Manag Res2010;2:293-301 PMCID:PMC3033035

[97] Guo W,Meyers PA,Huvos AG.Mechanisms of methotrexate resistance in osteosarcoma..Clin Cancer Res1999;5:621-7

[98] Rohde JM,Liu L,Yasgar A.Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors..Bioorg Med Chem2018;26:1727-39 PMCID:PMC5891386

[99] Mullarky E,Beheshti Zavareh R,Gomes AP.Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers..Proc Natl Acad Sci U S A2016;113:E1585 PMCID:PMC4801277

[100] Weinstabl H,Rinnenthal J,Ettmayer P.Intracellular trapping of the selective phosphoglycerate dehydrogenase (PHGDH) inhibitor BI-4924 disrupts serine biosynthesis..J Med Chem2019;62:7976-97

[101] Wang Q,Liu P,Liu Y.Rational design of selective allosteric Inhibitors of PHGDH and serine synthesis with anti-tumor activity..Cell Chem Biol2017;24:55-65 PMCID:PMC5915676

[102] Reid MA,Liu S,Liu P.Serine synthesis through PHGDH coordinates nucleotide levels by maintaining central carbon metabolism..Nat Commun2018;9:5442 PMCID:PMC6303315

[103] Pacold ME,Chan SH,Lewis CA.A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate..Nat Chem Biol2016;12:452-8 PMCID:PMC4871733

[104] Ravez S,Marteau R,Frédérick R.Challenges and opportunities in the development of serine synthetic pathway inhibitors for cancer therapy..J Med Chem2017;60:1227-37

[105] Sharif T,Dai C,Lee K.Phosphoglycerate dehydrogenase inhibition induces p-mTOR-independent autophagy and promotes multilineage differentiation in embryonal carcinoma stem-like cells..Cell Death Dis2018;9:990 PMCID:PMC6155240

[106] Sim WC,Sim H,Jung SH.Downregulation of PHGDH expression and hepatic serine level contribute to the development of fatty liver disease..Metabolism2020;102:154000